Gestor Editorial

Nuevo Usuario
Revisiones en Cáncer 00083 / http://dx.doi.org/10.20960/revcancer.00083
Resumen| PDF

Revisión

Enfermedad trofoblástica gestacional

Gloria Marquina, María José Ginemo, Daniele Palazzin, Antonio Casado

Prepublicado: 2024-11-20

Logo Descargas   Número de descargas: 81      Logo Visitas   Número de visitas: 41      Citas   Citas: 0

Compártelo:


La enfermedad trofoblástica gestacional (ETG) engloba diferentes lesiones premalignas y malignas raras que surgen fruto de una gestación anormal. Las formas malignas se conocen como neoplasia trofoblástica gestacional (NTG), que, aunque se diagnostiquen con enfermedad metastásica, tienen un pronóstico excelente si se tratan adecuadamente por equipos expertos. En este artículo realizaremos un repaso de la patogenia, factores de riesgo, incidencia, diagnóstico y tratamiento de la ETG y de la NTG.

Palabras Clave: Gestación molar. Enfermedad trofoblástica gestacional. Neoplasia trofoblástica gestacional. Coriocarcinoma. Neoplasia posmolar. Tumor trofoblástico.



Hoffman BL, Schorge JO, Halvorson LM, et al. (editors). Enfermedad trofoblástica gestacional. In: Williams Ginecología, 4.ª edición. McGraw-Hill Education; 2020.
Lurain JR. Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obstet Gynecol 2010;203(6):531-9.
DOI: 10.1016/j.ajog.2010.06.073
Gockley AA, Melamed A, Joseph NT, Clapp M, Sun SY, Goldstein DP, et al. The effect of adolescence and advanced maternal age on the incidence of complete and partial molar pregnancy. Gynecol Oncol 2016;140(3):470-3.
DOI: 10.1016/j.ygyno.2016.01.005
Savage PM, Sita-Lumsden A, Dickson S, Iyer R, Everard J, Coleman R, et al. The relationship of maternal age to molar pregnancy incidence, risks for chemotherapy and subsequent pregnancy outcome. J Obstet Gynaecol 2013;33(4):406-11.
DOI: 10.3109/01443615.2013.771159
Sebire NJ, Foskett M, Fisher RA, Rees H, Seckl M, Newlands E. Risk of partial and complete hydatidiform molar pregnancy in relation to maternal age. BJOG Int J Obstet Gynaecol 2002;109(1):99-102.
DOI: 10.1111/j.1471-0528.2002.t01-1-01037.x
Seckl MJ, Sebire NJ, Fisher RA, Golfer F, Massuger L, Sessa C. Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Of J Eur Soc Med Oncol 2013;24(6):vi39-50.
DOI: 10.1093/annonc/mdt345
Fisher RA, Maher GJ. Genetics of gestational trophoblastic disease. Best Pract Res Clin Obstet Gynaecol 2021;74:29-41.
DOI: 10.1016/j.bpobgyn.2021.01.004
Lu X, Gao Z, Qin D, Li L. A Maternal Functional Module in the Mammalian Oocyte-To-Embryo Transition. Trends Mol Med 2017;23(11):1014-23.
DOI: 10.1016/j.molmed.2017.09.004
Berkowitz RS, Goldstein DP. Current management of gestational trophoblastic diseases. Gynecol Oncol 2009;112(3):654-62.
DOI: 10.1016/j.ygyno.2008.09.005
Matsui H, Kihara M, Yamazawa K, Mitsuhashi A, Seki K, Sekiya S. Recent changes of the incidence of complete and partial mole in Chiba prefecture. Gynecol Obstet Invest 2007;63:7-10.
DOI: 10.1159/000094388
Eysbouts YK, Bulten J, Ottevanger PB, Thomas CMG, Ten Kate-Booij MJ, Van Herwaarden AE, et al. Trends in incidence for gestacional trophoblastic disease over the last 20 years in a population-based study. Gynecologic Oncology 2016;140:70-5.
DOI: 10.1016/j.ygyno.2015.11.014
Yuk JS, Baek JC, Park JE, Jo HC, Park JK, Cho IA. Incidence of gestational trophoblastic disease in South Korea: a longitudinal, population-based study. PeerJ 2019;20(7):e6490.
DOI: 10.7717/peerj.6490
Maisenbacher MK, Merrion K, Kutteh WH. Single-nucleotide polymorphism microarray detects molar pregnancies in 3 % of miscarriages. Fertil Steril 2019;112(4):700-6.
DOI: 10.1016/j.fertnstert.2019.06.015
Ning F, Hou H, Morse AN, Lash GE. Understanding and management of gestational trophoblastic disease. F1000Res 2019;8:F1000 Faculty Rev-428.
DOI: 10.12688/f1000research.14953.1
Yang J, Zong L, Wang J, Wan X, Feng F, Xiang Y. Epithelioid Trophoblastic Tumors: Treatments, Outcomes, and Potential Therapeutic Targets. J Cancer 2019;10(1):11-9.
DOI: 10.7150/jca.28134
Marquina G, Szewczyk G, Goffin F. The Rare of the Rarest: Placental Site Trophoblastic Tumor, Epithelioid Trophoblastic Tumor, Atypical Placental Site Nodule. Gynecol Obstet Invest 2024;89(3):239-46.
DOI: 10.1159/000536494
Coronado P, Marquina G, Diestro M, Alonso S, Sánchez-del-Río A, Hardisson D, et al. Guía de Asistencia Práctica Enfermedad trofoblástica gestacional. Prog Obstet Ginecol 2020;63(3):165-84.
Ngan HYS, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, et al. Diagnosis and management of gestational trophoblastic disease: 2021 update. Int J Gynaecol Obstet 2021;155(Suppl.1):86-93.
DOI: 10.1002/ijgo.13877
Kaur B. Pathology of gestational trophoblastic disease (GTD). Hematol Oncol Clin North Am 2024;38(6):1191-217.
DOI: 10.1016/j.hoc.2024.08.017
Lok C, Frijstein M, Van Trommel N. Clinical presentation and diagnosis of Gestational Trophoblastic Disease. Best Pract Res Clin Obstet Gynaecol. 2021;74:42-52.
DOI: 10.1016/j.bpobgyn.2020.12.001
Coopmans L, Larsson A, Joneborg U, Lok C, Van Trommel N. Surgical Management of Gestational Trophoblastic Disease. Gynecol Obstet Invest 2024;89(3):214-29.
DOI: 10.1159/000534065
Osborne RJ, Filiaci VL, Schink JC, Mannel RS, Behbakht K, Hoffman JS, et al. Second Curettage for Low-Risk Nonmetastatic Gestational Trophoblastic Neoplasia. Obstet Gynecol 2016;128(3):535-42.
DOI: 10.1097/AOG.0000000000001554
Alazzam M, Hancock BW, Tidy J. Role of hysterectomy in managing persistent gestational trophoblastic disease. J Reprod Med 2008;53(7):519-24.
Eysbouts YK, Massuger L, IntHout J, Lok CAR, Sweep F, Ottevanger PB. The added value of hysterectomy in the management of gestational trophoblastic neoplasia. Gynecologic Oncol 2017;145(3):536-42.
DOI: 10.1016/j.ygyno.2017.03.018
Kaur B, Short D, Fisher RA, Savage PM, Seckl MJ, Sebire NJ. Atypical placental site nodule (APSN) and association with malignant gestational trophoblastic disease; a clinicopathologic study of 21 cases. Int J Gynecol Pathol 2015;34(2):152-8.
DOI: 10.1097/PGP.0000000000000128
Jeremie G, Allias F, Trecourt A, Gaillot-Durand L, Bolze PA, Descotes F, et al. Molecular Analyses of Chorionic-Type Intermediate Trophoblastic Lesions: Atypical Placental Site Nodules are Closer to Placental Site Nodules Than Epithelioid Trophoblastic Tumors. Mod Pathol 2023;36(1):100046.
DOI: 10.1016/j.modpat.2022.100046
Price JM, Lo C, Abdi S, Winter MC, Coleman RE, Tidy J, et al. The Role of Computed Tomography Scanning of the Thorax in the Initial Assessment of Gestational Trophoblastic Neoplasia. Int J Gynecol Cancer 2015;25(9):1731-6.
DOI: 10.1097/IGC.0000000000000534
FIGO Oncology Committee. FIGO staging for gestational trophoblastic neoplasia 2000. FIGO Oncology Committee. Int J Gynaecol Obstet 2002;77(3):285-7.
DOI: 10.1016/S0020-7292(02)00063-2
Lawrie TA, Alazzam M, Tidy J, Hancock BW, Osborne R. First-line chemotherapy in low-risk gestational trophoblastic neoplasia. Cochrane Database Syst Rev 2016;2016(6):CD007102.
DOI: 10.1002/14651858.CD007102.pub4
Lybol C, Sweep FC, Harvey R, Mitchell H, Short D, Thomas CM, et al. Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia. Gynecol Oncol 2012;125(3):576-9.
DOI: 10.1016/j.ygyno.2012.03.003
Couder F, Massardier J, You B, Abbas F, Hajri T, Lotz JP, et al. Predictive factors of relapse in low-risk gestational trophoblastic neoplasia patients successfully treated with methotrexate alone. Am J Obstet Gynecol 2016;215(1):80.e1-7.
DOI: 10.1016/j.ajog.2016.01.183
Bower M, Newlands ES, Holden L, Short D, Brock C, Rustin GJ, et al. EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. J Clin Oncol 1997;15(7):2636-43.
DOI: 10.1200/JCO.1997.15.7.2636
Savage P, Winter M, Parker V, Harding V, Sita-Lumsden A, Fisher RA, et al. Demographics, natural history and treatment outcomes of non-molar gestational choriocarcinoma: a UK population study. BJOG 2020;127(9):1102-7.
DOI: 10.1111/1471-0528.16202
Alifrangis C, Agarwal R, Short D, Fisher RA, Sebire NJ, Harvey R, et al. EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. J Clin Oncol 2013;31(2):280-6.
DOI: 10.1200/JCO.2012.43.1817
Savage P, Kelpanides I, Tuthill M, Short D, Seckl MJ. Brain metastases in gestational trophoblast neoplasia: an update on incidence, management and outcome. Gynecol Oncol 2015;137(1):73-6.
DOI: 10.1016/j.ygyno.2015.01.530
Gestational trophoblastic diseases. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser 1983;692:7-81.
Frijstein MM, Lok CAR, Van Trommel NE, Ten Kate-Booij MJ, Massuger L, Van Werkhoven E, et al. Management and prognostic factors of epithelioid trophoblastic tumors: Results from the International Society for the Study of Trophoblastic Diseases database. Gynecol Oncol 2019;152(2):361-7.
DOI: 10.1016/j.ygyno.2018.11.015
Schmid P, Nagai Y, Agarwal R, Hancock B, Savage PM, Sebire NJ, et al. Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study. Lancet 2009;374(9683):48-55.
DOI: 10.1016/S0140-6736(09)60618-8
Froeling FEM, Ramaswami R, Papanastasopoulos P, Kaur B, Sebire NJ, Short D, et al. Intensified therapies improve survival and identification of novel prognostic factors for placental-site and epithelioid trophoblastic tumours. Br J Cancer 2019;120(6):587-94.
DOI: 10.1038/s41416-019-0402-0
Joneborg U, Coopmans L, Van Trommel N, Seckl M, Lok CAR. Fertility and pregnancy outcome in gestational trophoblastic disease. Int J Gynecol Can 2021;31(3):399-411.
DOI: 10.1136/ijgc-2020-001784
Frijstein MM, Lok CAR, Short D, Singh K, Fisher RA, Hancock BW, et al. The results of treatment with high-dose chemotherapy and peripheral blood stem cell support for gestational trophoblastic neoplasia. Eur J Can 2019;109:162-71.
DOI: 10.1016/j.ejca.2018.12.033
Mangili G, Sabetta G, Cioffi R, Rabaiotti E, Candotti G, Pella F, et al. Current Evidence on Immunotherapy for Gestational Trophoblastic Neoplasia (GTN). Cancers (Basel) 2022;14(11):2782.
DOI: 10.3390/cancers14112782
Balachandran K, Salawu A, Ghorani E, Kaur B, Sebire NJ, Short D, et al. When to stop human chorionic gonadotrophin (hCG) surveillance after treatment with chemotherapy for gestational trophoblastic neoplasia (GTN): A national analysis on over 4,000 patients. Gynecol Oncol 2019;155(1):8-12.
DOI: 10.1016/j.ygyno.2019.07.024
Bouchard-Fortier G, Ghorani E, Short D, Aguiar X, Harvey R, Unsworth N, et al. Following chemotherapy for gestational trophoblastic neoplasia, do residual lung lesions increase the risk of relapse? Gynecol Oncol 2020;158(3):698-701.
DOI: 10.1016/j.ygyno.2020.06.483
Lok CA, Van der Houwen C, Ten Kate-Booij MJ, Van Eijkeren MA, Ansink AC. Pregnancy after EMA/CO for gestational trophoblastic disease: a report from The Netherlands. BJOG 2003;110(6):560-6.
DOI: 10.1046/j.1471-0528.2003.02419.x
Cortes-Charry R, Hennah L, Froeling FEM, Short D, Aguiar X, Tin T, et al. Increasing the human chorionic gonadotrophin cut-off to ≤ 1000 IU/l for starting actinomycin D in post-molar gestational trophoblastic neoplasia developing resistance to methotrexate spares more women multi-agent chemotherapy. ESMO Open 2021;6(3):100110.
DOI: 10.1016/j.esmoop.2021.100110
Jareemit N, Horowitz NS, Goldstein DP, Berkowitz RS, Elias KM. Outcomes for relapsed versus resistant low risk gestational trophoblastic neoplasia following single-agent chemotherapy. Gynecol Oncol 2020;159(3):751-7.
DOI: 10.1016/j.ygyno.2020.09.046
Winter MC, Tidy JA, Singh K, Sarwar N, Aguiar X, Seckl MJ. Efficacy analysis of single-agent carboplatin AUC4 2-weekly as second-line therapy for methotrexate-resistant (MTX-R) low risk gestational trophoblastic neoplasia (GTN). Gynecol Oncol 2023;175:66-71.
DOI: 10.1016/j.ygyno.2023.05.072
Mora PAR, Sun SY, Velarde GC, Filho JR, Uberti EH, Dos Santos Esteves APV, et al. Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia? Gynecol Oncol 2019;153(2):277-85.
DOI: 10.1016/j.ygyno.2019.03.005
You B, Bolze PA, Lotz JP, Massardier J, Gladieff L, Joly F, et al. Avelumab in Patients with Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial. J Clin Oncol 2020;38(27):3129-37.
DOI: 10.1200/JCO.20.00803
Baas IO, Westermann AM, You B, Bolze PA, Seckl M, Ghorani E. Immunotherapy for GTN: a new paradigm. Gynecol Obstet Invest 2024;89(3):230-8.
DOI: 10.1159/000533972
Hanna RK, Soper JT. The role of surgery and radiation therapy in the management of gestational trophoblastic disease. The Oncologist 2010;15(6):593-600.
DOI: 10.1634/theoncologist.2010-0065

Artículos más populares


Editado en Madrid por:
Diseño y Desarrollo web Im3diA comunicación

Una cookie o galleta informática es un pequeño archivo de información que se guarda en su navegador cada vez que visita nuestra página web. La utilidad de las cookies es guardar el historial de su actividad en nuestra página web, de manera que, cuando la visite nuevamente, ésta pueda identificarle y configurar el contenido de la misma en base a sus hábitos de navegación, identidad y preferencias. Las cookies pueden ser aceptadas, rechazadas, bloqueadas y borradas, según desee. Ello podrá hacerlo mediante las opciones disponibles en la presente ventana o a través de la configuración de su navegador, según el caso. En caso de que rechace las cookies no podremos asegurarle el correcto funcionamiento de las distintas funcionalidades de nuestra página web. Más información en el apartado “POLÍTICA DE COOKIES” de nuestra página web.

Rechazar